Perampanel in lissencephaly-associated epilepsy

Satoru Ikemoto; Shin-Ichiro Hamano; Yuko Hirata; Ryuki Matsuura; Reiko Koichihara

doi:10.1016/j.ebcr.2019.01.001

Perampanel in lissencephaly-associated epilepsy

Epilepsy Behav Case Rep. 2019 Jan 11:11:67-69. doi: 10.1016/j.ebcr.2019.01.001. eCollection 2019.

Authors

Satoru Ikemoto^{1

2}, Shin-Ichiro Hamano^{1

3}, Yuko Hirata^{1

2}, Ryuki Matsuura¹, Reiko Koichihara³

Affiliations

¹ Division of Neurology, Saitama Children's Medical Center, 2-1 Shin-toshin, Chuou-ku, Saitama-city, Saitama 330-8777, Japan.
² Department of Pediatrics, The Jikei University School of Medicine, 3-19-18 Nishi-shinbashi, Minato-ku, Tokyo 105-8471, Japan.
³ Department for Child Health and Human Development, Saitama Children's Medical Center, 2-1 Shin-toshin, Chuou-ku, Saitama-city, Saitama 330-8777, Japan.

Abstract

We retrospectively investigated whether perampanel (PER) could serve as an alternative for treating drug-resistant seizures in lissencephaly. We investigated the following data: age at onset of epilepsy, age at start of PER, etiology, brain MRI findings, seizure type, seizure frequency, adverse effects, and concomitant anti-epileptic drugs. There were 5 patients with lissencephaly, including 2 with Miller-Dieker syndrome. Four out of five patients exhibited ≥ 50% seizure reduction. Myoclonic seizures disappeared in 1 patient. PER was an effective adjunctive anti-seizure drug in our series of patients with lissencephaly.

Keywords: AMPA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid; DRPLA, dentatorubral–pallidoluysian atrophy; GTCS, generalized tonic–clonic seizures; Lissencephaly; NMDA, N-methyl-d-aspartate; Neuronal migration disorder; PER, perampanel; Perampanel.

Publication types

Case Reports